AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down – Here’s What Happened

AbCellera Biologics Inc. (NASDAQ:ABCL) shares gapped down before the market opened on Wednesday . The stock had previously closed at $9.76, but opened at $9.22. AbCellera Biologics shares last traded at $9.6910, with a volume of 2,981,112 shares changing hands.

Key Stories Impacting AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: ABCL635 delivered positive Phase 2 results. The non-hormonal treatment met its primary efficacy endpoints, significantly reducing the frequency and severity of moderate-to-severe hot flashes. The results represent an important clinical validation for AbCellera’s first internally developed pipeline candidate and helped drive a sharp increase in the stock. AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results
• Positive Sentiment: Analyst optimism increased. Truist raised its price target for AbCellera from $12 to $30 and maintained a “buy” rating, reflecting the potential commercial value of ABCL635 and a more favorable view of the company’s pipeline. Truist Raises AbCellera Price Target
• Positive Sentiment: Trading activity signals increased bullish speculation. Investors purchased approximately 16,666 ABCL call options, about 151% above typical daily volume. This can amplify near-term momentum, though options activity is speculative rather than a measure of fundamental value. Investors Buy Large Volume of AbCellera Biologics Call Options
• Neutral Sentiment: Investors are divided on the longer-term outlook. Some analysts view the Phase 2 results as a major pipeline breakthrough, while others argue that the broader platform story is weakening and that additional development and regulatory milestones are needed before ABCL635 can support a sustained commercial revaluation. AbCellera Excellent Phase 2 Data in Menopause
• Negative Sentiment: AbCellera announced a proposed $200 million public offering. Issuing common shares and pre-funded warrants will provide cash for development but may dilute existing shareholders and could pressure the stock after its recent rally. AbCellera Announces Proposed Public Offering
• Negative Sentiment: Valuation risk has become more prominent. One analysis estimated ABCL could be about 33% overvalued following the Phase 2 announcement, highlighting the stock’s substantial run-up relative to AbCellera’s still-negative earnings, limited quarterly revenue and need for further clinical progress. AbCellera Could Be 33% Overvalued

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald boosted their target price on AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Stifel Nicolaus upped their price objective on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Truist Financial lifted their target price on shares of AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen downgraded shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.83.

AbCellera Biologics Stock Up 2.9%

The firm has a market cap of $3.08 billion, a P/E ratio of -18.59 and a beta of 1.20. The business has a fifty day simple moving average of $6.35 and a 200-day simple moving average of $4.77.

AbCellera Biologics (NASDAQ:ABCL) last released its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The business had revenue of $4.05 million during the quarter, compared to analysts’ expectations of $7.85 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. On average, sell-side analysts anticipate that AbCellera Biologics Inc. will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On AbCellera Biologics

Institutional investors have recently modified their holdings of the stock. SEB Asset Management AB purchased a new position in AbCellera Biologics in the first quarter worth about $1,188,000. Virtu Financial LLC bought a new position in shares of AbCellera Biologics during the 4th quarter valued at $619,000. Hsbc Holdings PLC lifted its holdings in AbCellera Biologics by 375.4% in the fourth quarter. Hsbc Holdings PLC now owns 117,031 shares of the company’s stock valued at $401,000 after acquiring an additional 92,414 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of AbCellera Biologics in the first quarter worth approximately $46,000. Finally, Ground Swell Capital LLC purchased a new position in shares of AbCellera Biologics during the 1st quarter worth $55,000. 61.42% of the stock is owned by hedge funds and other institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.